

## C-CAMP joins CARB-X to combat anti-microbial resistance

05 March 2019 | News

**CARB-X GAN brings together 10 world-class organizations from six countries (Denmark, Germany, India, Switzerland, United Kingdom, United States) into a single global network of expertise.**



The Centre for Cellular and Molecular Platforms – C-CAMP, a Department of Biotechnology - DBT, Government of India initiative, has joined the CARB-X Global Accelerator Network (GAN) for projects funded by CARB-X. CARB-X is the world's largest public-private partnership devoted to early development antibacterial R&D. C-CAMP is excited to join the global network and is the only accelerator in this network for all regions outside of USA and Europe. This was announced globally on February 26, 2019.

The spread of drug-resistant bacteria, also known as superbugs, is a growing threat to public health and a concerted global effort is needed to develop new therapeutics, diagnostics and preventatives to combat drug-resistant bacteria. The CARB-X GAN is a one-of-a-kind powerhouse of knowhow in antibacterial drug development, the development of rapid diagnostics, business and regulatory strategy, and other highly specialized areas essential to accelerating CARB-X's portfolio of funded projects targeting drug-resistant bacteria.

CARB-X GAN brings together 10 world-class organizations from six countries (Denmark, Germany, India, Switzerland, United Kingdom, United States) into a single global network of expertise to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects. The CARB-X GAN now comprises of: Centre for Cellular and Molecular Platforms - C-CAMP (Bengaluru, India), California Life Sciences Institute - CLSI (California, USA), MassBio (Boston, USA), RTI International (North Carolina, USA), the Wellcome Trust (London, UK), BaselArea.Swiss (Basel, Switzerland), BiInnovation Institute (Copenhagen, Denmark), Foundation for Innovative New Diagnostics - FIND (Geneva, Switzerland), German Center for Infection Research - DZIF (Braunschweig, Germany), and Institute for Life Sciences Entrepreneurship - ILSE (New Jersey, USA).

Speaking about the partnership, Dr. Taslimarif Saiyed, CEO and Director, C-CAMP, said "Antimicrobial Resistance is a major global health challenge and more so in India. We are excited about joining the CARB-X Global Accelerator Network, which supports innovative research targeting AMR in India and elsewhere in the world. We look forward to working with CARB-X-funded companies to support their innovative product development and collaborating with other accelerators in the network."

Kevin Outtersen, Executive Director of CARB-X and Boston University law professor said, "We are expanding our accelerator network to increase support for the development of new antibiotics, rapid diagnostics, vaccines and other life-saving products that the world so urgently needs to fight the rise of drug-resistant bacteria. Antibacterial product development is challenging,

and CARB-X's portfolio is growing rapidly. As a group, the Global Accelerator Network is an outstanding source of expertise and forceful ally in the global fight against drug-resistant bacteria.”